(RTTNews) - Regeneron Pharmaceuticals (REGN) announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD or aflibercept injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion, including those with central, branch and hemiretinal vein occlusions. In the trial, patients treated with EYLEA HD every 8 weeks experienced non-inferior vision gains compared to those treated with the approved monthly dosing regimen of EYLEA Injection 2 mg, the current standard of care. Also, about 90% of EYLEA HD patients were able to maintain 8-week dosing intervals through 36 weeks.
All currently FDA-approved anti-VEGF therapies for retinal vein occlusion require monthly dosing. The company said these data will be submitted to regulatory authorities around the world, with a submission to the FDA planned for the first quarter of 2025.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
